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Summary
Objectives: Osteoarthritis (OA) is considered a polygenic disease controlled by the expression of genetic factors. Genes encoding for
cytokines have been associated with susceptibility for joint OA and interleukin (IL)-6 gene is also supposed to be involved in the cartilage
degradation process. In this caseecontrol study, we evaluated for the ﬁrst time whether the risk of hip OA might be inﬂuenced by the174 IL-6
gene polymorphism.
Methods: The distribution of IL-6 genotypes was evaluated in 75 patients affected by hip OA and in 107 age- and sex-matched controls.
Results: The distribution of IL-6 genotypes in (1) patients with hip OA: 33 GG, 30 GC, 12 CC and (2) control subjects: 34 GG, 40 GC, 33 CC.
The frequency of the CC genotype was signiﬁcantly higher in control patients (PZ 0.02). Logistic regression analysis indicated that the
presence of the CC genotype is independently associated with a decreased risk of OA (odds ratio 0.4 [95% conﬁdence interval 0.1e0.9],
PZ 0.04).
Conclusions: Primary OA of the hip has an important genetic component and variations of genes encoding for inﬂammatory cytokines, such as
IL-6, may play an important role in the series of events responsible for the pathophysiology of OA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The incidence of osteoarthritis (OA) has increased in
western countries in the last decades, accordingly with the
demographic phenomenon of aging population1. Although
many risk factors have been associated with OA, including
age, previous injury, obesity, diet, hormone therapy, and
smoking habits2,3, the pathogenesis of OA is still incom-
pletely characterized. Cellular and molecular inﬂammatory
mechanisms may be important in the development of OA, as
suggested by the accumulation of inﬂammatory cells and
mediators in the site of cartilage damage and degeneration.
Many studies suggest that primary OA of the hip has an
important genetic component and OA is considered a poly-
genic disease controlled by the expression of genetic
factors. Also, cytokine genes have a relevant role in
regulating the catabolic/anabolic balance of articular carti-
lage, and recent studies4,5 have conﬁrmed the association
of the interleukin (IL)-1 gene cluster and IL-1 receptor
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Received 22 November 2004; revision accepted 14 July 2005.1antagonist (IL-1RA) with radiographic signs of OA of the hip.
In this setting, a crucial role has been hypothesized for IL-6,
which is produced by several cell types and plays a key role
in driving the acute inﬂammatory response. The human IL-6
gene is mapped to chromosome 7p21-24 with an upstream
promoter containing 303 bp. A single nucleotide polymor-
phism (SNP) has been described at position 174 of the
promoter region of the IL-6 gene, resulting in three possible
genotypes, GG, GC, and CC. This polymorphism has been
associated with the prevalence, incidence, and/or prognosis
of a variety of diseases, such as Alzheimer’s disease,
atherosclerosis, cardiovascular disease, cancer, non-in-
sulin-dependent diabetes mellitus, osteoporosis, sepsis,
and systemic-onset juvenile chronic arthritis6.
In this caseecontrol study, we evaluated for the ﬁrst time
whether the risk of hip OA might be inﬂuenced by the IL-6
gene polymorphism. Seventy-ﬁve patients affected by hip
OA and 107 age- and sex-matched controls were studied.
The distribution of IL-6 genotypes in (1) patients with hip
OA: 33 GG, 30 GC, 12 CC and (2) control subjects: 34 GG,
40 GC, 33 CC. The frequency of the CC genotype was
signiﬁcantly higher in control patients (PZ 0.02). Logistic
regression analysis indicated that the presence of the CC
genotype is independently associated with a decreased risk
of OA (odds ratio 0.4 [95% conﬁdence interval (CI)
0.1e0.9], PZ 0.04).025
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genes encoding for inﬂammatory cytokines, such as IL-6,
may play an important role in the series of events
responsible for the pathophysiology of OA.
Materials and methods
Patients and controls were recruited among subjects
consecutively admitted to the Department of Orthopedics at
the A. Gemelli University Hospital of Rome, Italy, from
October 2003 to March 2004. All patients underwent
anterioreposterior and axillary hip radiographs and ante-
ro-posterior hand radiographs using standard procedures.
Diagnosis of hip OA was made according to established
criteria7, submitting all patients to plain pelvic radiograph at
entry into the study. Antero-posterior radiograph was
performed with the patient standing on both legs. The
patient’s feet were 15(G 5( internally rotated. The X-ray
beam was horizontal, perpendicular to the table. The source
to ﬁlm distance was 100 cm. Radiographs were assessed
by one expert reader. For quantitative measurement, the
interbone distance at the narrowest point was measured in
millimeters using a 0.1 mm graduated magnifying glass laid
directly over the radiograph. In addition, joint space
narrowing was graded 0e3 using a radiographic atlas8.
Overall severity of OA was graded using the Kellgren and
Lawrence (KL) scale9. All patients selected as cases had
a minimal joint space %1.5 mm, their KL score was 3e4,
and all of them underwent surgery for total hip arthroplasty.
Otherwise, none of the cases had bilateral hip OA and the
major number of these patients had superolateral hip OA
with an indeterminate pattern. Generalized OA (GOA) was
deﬁned by the hypothesis that OA found in the hand is an
indicator of disease in other large joints. An individual was
considered to have GOA if more than three interphalangeal
joints scored at KL grades 2e4 (see Refs.9,10). With these
criteria, none of the studied individuals had GOA.
Subjects matching the cases for age and sex, without
clinical and radiographical evidence of OA, were used as
controls. These subjects had no relationship with cases and
no family history of OA. Controls were enrolled between
subjects who were admitted to the ambulatory of the
Department of the Orthopedics for post-traumatic injuries or
other symptomatic problems which did not correlate with
OA. All control subjects underwent clinical examination and
X-ray evaluation, in order to exclude the presence of hip
OA.
A total of 100 patients and 150 controls were initially
selected. Then, subjects affected by tumors, chronic
inﬂammatory diseases, infective diseases, and autoimmune
diseases were excluded. After excluding these cases,
a total of 75 patients with hip OA and 107 controls were
enrolled.
All subjects were Caucasians from central and southern
Italy and belonged to independent pedigrees. For all
individuals enrolled in the study, a complete medical history
was collected and included smoking habit, hormonal or
metabolic disorders, and previous joint injury. Body Mass
Index (BMI) was calculated as weight/height2 ratio. In-
formed consent was obtained from all patients. The study
protocol was accepted by the Ethics Committee of our
University Hospital.
Peripheral blood samples were obtained from all subjects
and nucleic acid isolation was carried out from 200 ml of
peripheral blood by using a DNA extraction kit (NucleoSpin
Blood QuickPure, Macherey-Nagel, Duren, Germany), asrecommended by the supplier. Genomic DNA was assayed
with polymerase chain reaction (PCR) for the detection of
IL-6 gene, using the published primer set: 5#-TGACTTC
AGCTTTACTCTTTGT-3# (sense primers) and 5#-
CTGATTGGAAACCTTATTAGG-3# (antisense primers).
Brieﬂy, PCR reaction, containing 0.2 mmol/l of each primer,
0.2 mmol/l of Deoxyribonucleoside Triphosphates (dNTPs)
(Boehringer GmbH, Mannheim, Germany), 1.5 mmol/l
MgCl2, and 2.5 U of AmpliTaq polymerase (PerkineElmer,
Cetus, Norwalk, CT) in a ﬁnal volume of 20 ml, was
performed in a GeneAmp PCR System 9700 (Perki-
neElmer) with an initial denaturation step of 10 min at
94(C and a ﬁnal extension step of 10 min at 72(C. The
following thermal proﬁle was repeated for 35 cycles:
denaturation for 1 min at 94(C, annealing for 1 min and
35 s at 55(C and extension for 1 min at 72(C. The
ampliﬁed sequence was digested by SfaNI restriction
enzyme (New England BioLabs, Beverly, Massachusetts,
USA) at 37(C overnight. The digested products were
electrophoresed in 2% agarose gel and visualized by
ethidium bromide staining. The GG genotype corresponded
to the presence of 140 and 58 bp fragments. The GC
genotype corresponded to the presence of 198, 140, and
58 bp fragments. The CC genotype corresponded to
a 198 bp fragment.
Demographic and clinical data between groups were
compared by c2 test and by t test. Genotype and allele
frequencies were compared by c2 test. Odds ratios were
calculated with 95% CI. To estimate the association
between genotype and OA, a logistic regression analysis
was used (intercooled stata 6.0 (STATA) Statistics/Data
Analysis STATA Corporation). Statistical signiﬁcance was
established at P! 0.05.
Results
There were no signiﬁcant differences between groups in
terms of age, sex and mean BMI. In the patient group, the
mean age was 70.4G 7.9 years. In the control group, the
mean age was 71.7G 10.8 years (PZ 0.3). The male/
female ratio was 30/45 in patients and 55/52 in controls
(PZ 0.1). In addition mean BMIs were not statistically
different between groups, respectively, 28.05G 4.09 in
patients with hip OA and 28.4G 2.82 in the control group
(PZ 0.47).
The distribution of IL-6 genotypes and alleles in cases
and controls is shown in Table I. Genotypes were in
HardyeWeinberg equilibrium. In 75 patients with hip OA,
the genotype distribution was 33 GG, 30 GC, 12 CC. Such
distribution differed signiﬁcantly from that observed in the
107 control subjects: 34 GG, 40 GC, 33 CC. The frequency
of the CC genotype in controls was almost two times higher
than in patients (30.8% vs 16.0%, PZ 0.02). In contrast,
the frequency of the GG genotype was higher in subjects
Table I
IL-6 genotype and allele distribution between groups
OA (nZ 75) Controls (nZ 107) P
Genotypes
G/G 33 34 0.09
G/C 30 40 0.7
C/C 12 33 0.022
Alleles
G 96 108
C 54 106 0.01
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statistical signiﬁcance (44.0% vs 31.8%, PZ 0.09). The C
allele was found in 49.5% of controls subjects and in 36.0%
of patients, while the G allele was detected in 64.0% of
patients with OA and in 50.5% of controls (PZ 0.01).
A logistic regression analysis (Table II) showed that the
CC genotype is independently associated with reduced risk
of OA of the hip (odds ratio 0.4 [95% CI 0.1e0.9], PZ 0.04).
Discussion
Inﬂammatory mechanisms play a crucial role in the
pathogenesis and evolution of cartilage degradation. A
large body of evidence suggests that lymphocytes, macro-
phages, and several forms of soluble inﬂammatory media-
tors are important in degenerative rheumatologic and
orthopedic diseases. OA is characterized by degeneration
of cartilage, which is expression of inﬂammatory reaction11.
Recent studies have suggested that OA might be consid-
ered a chronic inﬂammatory disorder12, and elevated levels
of IL-1, tumor necrosis factor-a, IL-6 and other acute-phase
proteins are found in patients with cartilage degradation13.
Genes encoding for cytokines have been associated with
susceptibility for joint OA. Recent studies indicate a role for
the IL-1 gene cluster and the IL-1 receptor antagonist (IL-
1RA) gene in the development of OA of the hip4,5. IL-6 gene
is also supposed to be involved in the cartilage degradation
process: in fact it is demonstrated that IL-6 expression is
strongly induced in articular chondrocytes by IL-1 (see
Ref.14). Importantly, the G allele of the 174 IL-6 gene
polymorphism has been associated with an increased
transcriptional response in vitro to stimuli, such as
endotoxin or IL-1 (see Refs.6,15). In addition, Fishman
et al.6 have demonstrated that non-stimulated IL-6 concen-
trations are associated with the G allele in healthy
individuals. Moreover, a recent study where healthy
individuals homozygous for the respective alleles were
exposed to a standardized inﬂammatory stimulus obtained
by vaccination against Salmonella typhii has shown that the
174 GOC SNP in the promoter region of the IL-6 gene is
functional in vivo with an increased inﬂammatory response
associated with the G allele16. Our data suggest that IL-6
gene polymorphism could play a role in the process of the
cartilage degradation. IL-6 in fact regulates production of
many acute-phase proteins17, promoting and maintaining
the inﬂammatory phenotype. Because this interaction and
ampliﬁcation process would change on the basis of IL-6
levels, the clinical relevance of the IL-6 gene polymorphism
is based on the fact that its gene variants inﬂuence levels
and functional activity of the protein. In this sense our
results show that the CC genotype of the 174 G/C
polymorphism of IL-6 gene promoter determines a lower
risk proﬁle for osteoarthritic disease. We also suggest that
the lack of association between the GG genotype and an
increased risk of OA could be due to the limited number of
patients involved in this study. This study has some
Table II
Risk factors of OA based on logistic regression analysis
Odds ratio CI (95%) P
C/C genotype 0.4 0.1e0.9 0.04
G/C genotype 0.7 0.4e1.5 0.5
Sex M 0.69 0.3e1.2 0.2
BMI 0.98 0.9e1.08 0.79
Age 0.99 0.9e1.02 0.66potential limitations. The size of the study population is
relatively small and our ﬁndings need to be conﬁrmed in
larger samples. The association between the IL-6 gene
polymorphism and OA should be tested in different ethnic
groups. This is a caseecontrol study and a possible survival
bias cannot be excluded for the group of patients with OA.
Finally, we cannot exclude that the observed association
depends on a gene in linkage disequilibrium with the IL-6
gene and further studies would be necessary to evaluate
the real role of the 174 G/C polymorphism of IL-6 gene
promoter in OA.
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